Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Medipolis GMP, a Finnish company based in Oulu, and Bioton SA, a Polish pharmaceutical company, have signed a licensing agreement on the manufacturing technology research project of an insulin analog used in treating diabetes. The licensing agreement is the final breakthrough for Medipolis GMP?s insulin analog manufacturing method that is a solution for producing more affordable alternatives to a growing global health problem.
The Finnish biopharmaceutical company Medipolis GMP Ltd and the Polish pharmaceutical company Bioton SA have concluded a technology licensing agreement. The agreement is worth EUR 5.3 million
http://www.heraldonline.com/2012/09/20/4277516/ground-communications-oulu-based.html
The Finnish biopharmaceutical company Medipolis GMP Ltd and the Polish pharmaceutical company Bioton SA have concluded a technology licensing agreement. The agreement is worth EUR 5.3 million
http://www.heraldonline.com/2012/09/20/4277516/ground-communications-oulu-based.html